J. Donahue to Long QT Syndrome
This is a "connection" page, showing publications J. Donahue has written about Long QT Syndrome.
Connection Strength
1.933
-
Donahue JK. Editorial commentary: The mundane and the profound of QT prolongation in the opioid abuse crisis. Trends Cardiovasc Med. 2024 Jul; 34(5):286-287.
Score: 0.856
-
Donahue JK. Sequencing of uncertain significance. J Cardiovasc Electrophysiol. 2018 01; 29(1):105-106.
Score: 0.580
-
Donahue JK. Advice for management of the long-QT patient. J Cardiovasc Electrophysiol. 2010 Aug 01; 21(8):902-4.
Score: 0.343
-
Lehnart SE, Ackerman MJ, Benson DW, Brugada R, Clancy CE, Donahue JK, George AL, Grant AO, Groft SC, January CT, Lathrop DA, Lederer WJ, Makielski JC, Mohler PJ, Moss A, Nerbonne JM, Olson TM, Przywara DA, Towbin JA, Wang LH, Marks AR. Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation. 2007 Nov 13; 116(20):2325-45.
Score: 0.072
-
Bauer A, Donahue JK, Voss F, Becker R, Kraft P, Senges JC, Kelemen K, Katus HA, Schoels W. Pro- and antiarrhythmic effects of fast cardiac pacing in a canine model of acquired long QT syndrome. Naunyn Schmiedebergs Arch Pharmacol. 2004 Apr; 369(4):447-54.
Score: 0.056
-
Ibrahim MA, Do DV, Sepah YJ, Shah SM, Van Anden E, Hafiz G, Donahue JK, Rivers R, Balkissoon J, Handa JT, Campochiaro PA, Nguyen QD. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. BMC Pharmacol Toxicol. 2013 Jan 14; 14:7.
Score: 0.026